{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-013131","form_type":"8-K","ticker":"PTN","cik":"0000911216","company_name":"PALATIN TECHNOLOGIES INC","filed_at":"2023-10-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.367699+00:00","generated_at":"2026-06-09T21:30:10.185631+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Palatin prelim Q1: Vyleesi gross revenue $4.6M, net $2.1M, up 100% and 137% YoY","bullets":["Gross product revenue $4.6M (+11% qoq, +100% YoY); net product revenue $2.1M (+18% qoq, +137% YoY).","Prescriptions dispensed grew 14% over prior quarter and 88% over comparable quarter last year.","Seventh consecutive quarter of double-digit growth in product revenue and prescriptions dispensed.","CEO reports net revenue per prescription improving; net product revenue exceeds Vyleesi quarterly operating expenses.","All key metrics (new patient starts, refill rates, insurance reimbursement, new prescribers) showed positive trends."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-013131","json":"https://secwatch.observer/filing/0001654954-23-013131.json","markdown":"https://secwatch.observer/filing/0001654954-23-013131.md","text":"https://secwatch.observer/filing/0001654954-23-013131.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/911216/000165495423013131/0001654954-23-013131-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/911216/000165495423013131/ptn_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T21:30:10.185631+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"61ee6ec076e92137044d84e62e0f3f424b290b62","claim":"PALATIN TECHNOLOGIES INC reported first quarter of fiscal year 2024 ended September 30, 2023 results: revenue $4.6 million in gross product revenue; $2.1 million in net product revenue.","evidence_excerpt":"Preliminary Quarter Ended September 30, 2023 Vyleesi ® Product Revenue Results · 7 Consecutive Quarters of Double-Digit Growth in Product Revenue and Prescriptions Dispensed · $4.6 million in Gross Product Revenue o 11% growth over prior quarter; 100% growth over comparable quarter last year · $2.1 million in Net Product Revenue o 18% growth over prior quarter;","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/911216/000165495423013131/0001654954-23-013131-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of fiscal year 2024 ended September 30, 2023"},{"label":"Revenue","value":"$4.6 million in gross product revenue; $2.1 million in net product revenue"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}